Literature DB >> 3216776

Protein serotyping of Streptococcus pneumoniae based on reactivity to six monoclonal antibodies.

W D Waltman1, L S McDaniel, B Andersson, L Bland, B M Gray, C S Eden, D E Briles.   

Abstract

Six monoclonal antibodies to proteins of Streptococcus pneumoniae were tested in a dot blot assay for reactivity with 499 clinical isolates of pneumococci. Forty-four percent of the isolates reacted with at least one of the antibodies. Nineteen patterns of reactivity were identified and each designated as a provisional protein serotype. Protein serotyping identified pneumococcal strains independently of their capsular type and made it possible to differentiate strains within most capsular types. A protein serotyping system provides a new dimension to the phenotypic identification of S. pneumoniae and may eventually provide a basis for assessing the population structure of these organisms.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3216776     DOI: 10.1016/0882-4010(88)90018-6

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  8 in total

1.  Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae.

Authors:  D E Briles; M J Crain; B M Gray; C Forman; J Yother
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

Review 2.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

3.  A 43-kilodalton pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis of the amino-terminal sequence.

Authors:  D F Talkington; D L Crimmins; D C Voellinger; J Yother; D E Briles
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

4.  Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae.

Authors:  M J Crain; W D Waltman; J S Turner; J Yother; D F Talkington; L S McDaniel; B M Gray; D E Briles
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

5.  Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens.

Authors:  D E Briles; C Forman; J C Horowitz; J E Volanakis; W H Benjamin; L S McDaniel; J Eldridge; J Brooks
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

6.  Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types.

Authors:  L S McDaniel; D O McDaniel; S K Hollingshead; D E Briles
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

Review 7.  Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA).

Authors:  D E Briles; R C Tart; E Swiatlo; J P Dillard; P Smith; K A Benton; B A Ralph; A Brooks-Walter; M J Crain; S K Hollingshead; L S McDaniel
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

8.  The Modified Surface Killing Assay Distinguishes between Protective and Nonprotective Antibodies to PspA.

Authors:  Kristopher R Genschmer; Cintia F M Vadesilho; Larry S McDaniel; Sang-Sang Park; Yvette Hale; Eliane N Miyaji; David E Briles
Journal:  mSphere       Date:  2019-12-11       Impact factor: 4.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.